dor biopharma - 500 Beiträge pro Seite

[Mant]

http://www.dorbiopharma.com/index.htm

DOR BioPharma (WKN 873539) fokussiert sich seit seiner gründung im jahre 1987 auf die entwicklung von impfstoffen gegen biologische kampfstoffe, als auch die entwicklung von innovativen arzneimittel für die behandlung von nach wie vor nur schwer therapierbaren krankheiten (sog. unmet medical needs). in der geschäftseinheit bio-abwehr bzw. bio-terrorismus entwickelt DOR BioPharma auf basis biotechnologischer verfahren empfstoffe zum schutz vor den tödlichen ricin und botulinum toxinen.

das stärkste gift der welt ist 100.000-mal giftiger als das hochgiftige sarin.

botulinustoxin aus dem bakterium clostridium ist das stärkste natürliche gift der welt.
500 ml reichen, um die gesamte menschheit auszulöschen.

dor-biopharma ist das weltweit führende unternehmen, das noch im laufenden jahr eine multivalente impfung gegen alle drei relevanten botulinum-serotypen in die klinische
testphase bringen könnte.

das pentagon hat ein budget von 1,7 milliarden usd zur abwehr von bioterror (bio-shield).
darüber hinaus verfügt dor noch über eine impfung gegen ricin-toxine und ein medikament
gegen abstossreaktionen bei knochenmarktransplantationen in der klinischen erprobung.

in zeiten latenter bio-terrorgefahr könnte dor vervielfachungspotential haben.
mit einer mk von unter 20 millionen hat dor das zeug zum tenbagger - und zum totalverlust!

zugegeben, der chart sieht alles andere als einladend aus. doch ich habe mir ein paar stück ins depot gelegt.



kgv: neg
kuv: 16,5
mk: 17,7 m usd
akt. kurs: 0,35 usd


gruss. €

[Mant]

August 15 , 2005

DOR BioPharma Reports Second Quarter 2005 Financial Results and Reviews Achievements

Miami, FL. – August 15, 2005 - DOR BioPharma, Inc. (AMEX: DOR) (“DOR” or the “Company”), a biopharmaceutical company focused on the development of novel therapeutics and vaccines for unmet medical needs, announced today its financial results for the second quarter ended June 30, 2005.

The Company reported an improved net loss to shareholders of $541,412 or $0.01 per share for the second quarter of 2005, compared to $1,473,376 or $0.04 per share for the second quarter of 2004. Revenues attributable to grants for the second quarter of 2005 were $1,422,703, compared to zero in the second quarter of 2004. Research and development costs for the second quarter of 2005 were $736,905 compared to $990,013 for the second quarter of 2004. General and administrative expenses for the second quarter 2005 were $423,873 compared to $498,894 for the second quarter of 2004. The improved second quarter result was due to the September 2004 $5,173,298 million grant award from the National Institute of Allergy and Infectious Diseases (NIAID) for RiVaxTM. In May of 2005 the grant was increased to $6,433,316 based on a new renegotiated Facilities and Administrative (F&A) rate with the NIAID from which the Company drew down significantly in the second quarter. Additionally, a portion of the net reduction in second quarter expenses was related to a recovery of stock option expense for the variable treatment of options for employees in the amount of $284,855. Our cost of revenues for the three months ended June 30, 2005 was $829,639 compared to zero for the three months ended June 30, 2004. For the six months ended 2005, the Company reported an improved net loss to shareholders of $1,570,727 or $0.03 per share, compared to $3,139,386 or $0.08 per share for the six months ended June 30, 2004. For the six months ended 2005, revenues increased to $1,536,243, compared to $66,095 for the six months ended June 30, 2004.

For the six months ended 2005, research and development decreased to $1,466,891, compared to $1,689,524 for the six months ended June 30, 2004. In 2004, costs for research and development were higher due to the completion of the pivotal Phase III clinical trial of orBec®. For the six months ended 2005, general and administrative expenses decreased to $765,808, compared to $977,471 for the six months ended June 30, 2004. For the six months ended June 30, 2005, the cost of revenues was $919,852, compared to $59,486 for the same six month period ended June 30, 2004. These costs relate to payments made to subcontractors and universities in connection with the aforementioned grants.

While DOR`s second quarter 2005 financial results are substantially better than results reported in prior quarters for reasons previously described, the Company expects financial results for the remainder of the year to be more in line with past results.

"We are extremely pleased with the progress we have made so far in 2005," commented Michael T. Sember, President and Chief Executive Officer of DOR. "2005 has so far been marked by substantial advancement and important developments in all three of our lead programs. In particular, we look forward to filing a high quality NDA for orBec® for the treatment of the unmet medical need of intestinal Graft-versus-Host Disease as soon as possible. Our goal is to file the NDA before year end 2005."

DOR`s Second Quarter 2005 Highlights:

On April 15, 2005, DOR announced that the abstract describing orBec® Phase III Clinical Trial results was selected for presentation at the annual meeting of the American Association of Cancer Research.
On April 20, 2005, DOR announced its intention to file a New Drug Application (NDA) with the FDA for orBec® pursuant to its meeting with FDA.
On May 4, 2005, DOR announced the appointment of T. Jerome Madison, M.B.A., C.P.A., to the Board of Directors. Mr. Madison brings over 30 years of financial and pharmaceutical experience.
On June 15, 2005 DOR announced positive interim results from the Phase I Clinical trial of RiVaxTM. Results from the trial demonstrated that RiVaxTM is safe and immunogenic after immunization with three monthly injections of vaccine, with volunteers developing antibodies.
Subsequent Events:

On July 13, 2005, DOR announced that its compliance plan period was extended by the AMEX to October 15, 2005.
On July 20, 2005, DOR announced that it achieved the important milestone of the completion of downstream process development and fermentation with its manufacturing partner Cambrex in the development and manufacture of RiVaxTM.
On July 26, 2005, DOR announced that it entered into a joint development agreement with Dowpharma for the development of BT-VACCTM, DOR`s oral vaccine against Botulinum Toxin poisioning.
Selected Financial Data:

Statement of Operations Data
Quarter Ended June 30, 2005:

Net loss applicable to common stockholders ..............................($541,412)

Six months Ended June 30, 2005:

Net loss applicable to common stockholders ..............................($1,570,727)

Balance Sheet Data
As of June 30, 2005:

Cash and cash equivalents .......................................................$3,189,628
Working capital .......................................................................$2,574,553
Total shareholders` equity......................................................... $4,676,895



About DOR BioPharma, Inc.

DOR BioPharma, Inc. is a biopharmaceutical company focused on the development of biodefense vaccines and therapeutics for areas of unmet medical needs. Through its BioDefense Division, DOR is developing bioengineered vaccines designed to protect against the deadly effects of ricin toxin and botulinum toxin. DOR`s lead therapeutic product, orBec® (an oral formulation of beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed to treat inflammation in the mucosal lining of the intestine and stomach that can occur following allogeneic bone marrow and stem cell transplants. For further information regarding DOR BioPharma, please visit the Company`s website located at www.dorbiopharma.com.


Forward Looking Statements

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma`s current expectations about its future results, performance, prospects and opportunities. Where possible, DOR BioPharma has tried to identify these forward-looking statements by using words such as "anticipates," "believes", "intends", or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR BioPharma cannot assure you that it will be able to successfully develop or commercialize products based on its technology, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that, product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully enter into profitable biodefense contracts with the U.S. Government and other countries ,that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR BioPharma`s most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.

[ds1000]

schau` ins Yahoo-Forum, dort wird DOR intensiv diskutiert; bin im Herbst ein- und dann bei rd. 0,7 ausgestiegen; ich warte auf die Zulassung von OrBec im Herbst 2005

Servus

[Mant]

hi!

ich kann das forum leider nicht finden.
kannst du mit bitte einen link reinstellen.

dank und gruss. €

[ds1000]

http://messages.yahoo.com/?action=q&board=DOR

Interessant ist weiters, daß der Autor vom Gewinn-Extra, Michael Kordovsky, DOR in seinem Nanotechfond hat;
nachzulesen bei ariconsult.com; ISIN: AT000062058

Servus

[Mant]

hi ds100!


danke für die info!

was hast mit der isin der aua vor?
die könnte übrigens interessant werden, wenn die kerosinpreise wieder zurückkommen und der laden hoffentlich mal gewinne schreibt. die bewertung ist günstig.
aha! lustig!
du meintest at0000620588
kleine ursache - grosse wirkung!

ja, interessantes werte. nastech habe ich übrigens mal gehabt. die kommen mir einfach nicht in die schwarzen zahlen. doch der kurs entwicklet sich.
samsung ist eine meiner grössten positionen.

gruss. €